

COURSE FACULTY, IAS–USA STAFF, SCIENTIFIC LEADERSHIP BOARD, AND GOVERNANCE BOARD

FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as “commercial interests”) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The ACCME defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months. View the [Faculty Financial Disclosure Policy](#).

THE IAS–USA ANNUAL UPDATE ON HIV MANAGEMENT IN ATLANTA, GEORGIA

APRIL 18, 2024

Course Presenters and Panelists	
Carlos del Rio, MD Leon L. Haley, Jr MD Distinguished Professor of Medicine Executive Associate Dean for Faculty and Clinical Affairs Emory University Atlanta, GA	Dr del Rio reported receiving consulting fees from Roche Diagnostics. (Updated January 30, 2024)
Daniel C. Douek, MD, PhD Bethesda, MD	Dr Douek reported no relevant financial relationships with ineligible companies. (Updated March 27, 2024)
Steven K. Grinspoon, MD Chief, MGH Metabolism Unit Professor, Harvard Medical School Boston, MA	Dr Grinspoon reported serving as a consultant for Theratechnologies, Inc, and receiving grant support paid through his institution from KOWA Pharmaceuticals, Inc, Gilead Sciences, Inc, and ViiV Healthcare. (Updated March 30, 2024)
Sandra A. Springer, MD Professor of Medicine Yale School of Medicine New Haven, CT	Dr Springer reported receiving consulting fees from Alkermes Inc, and in-kind drug donations from Alkermes, Inc, and Indivior. (Updated February 19, 2024)
Melanie A. Thompson, MD Professor of Medicine Thacker & Thompson, MD Atlanta, GA	Dr Thompson reported serving on data monitoring boards for Excision Biotherapeutics. (Updated April 8, 2024)
Kimberly A. Workowski, MD Professor of Medicine Division of Infectious Diseases Emory University Atlanta, GA	Dr Workowski reported no relevant financial relationships with ineligible companies. (Updated April 1, 2024)

IAS–USA CME Planners and Reviewers	
Jeffrey L. Lennox, MD Professor of Medicine and Associate Dean for Clinical Research Emory University Vice Chair for Grady Affairs, Department of Medicine Atlanta, GA	Dr Lennox reported no relevant financial relationships with ineligible companies. (Updated April 1, 2024)
Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, AL	Dr Saag reported serving as a consultant for TFF Pharmaceuticals, Inc, and American Gene Technologies International, Inc. (Updated March 11, 2024)
Donna M. Jacobsen Executive Director/President	Ms Jacobsen reported no relevant financial affiliations with ineligible companies to disclose. (Updated March 16, 2024)

IAS–USA

San Francisco, CA

IAS–USA Boards

The nonstaff members of the [IAS–USA Scientific Advisory Board](#) and [Governance Board](#) are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.